Skip to main content

MECANISMOS DE REPRESION TRANSCRIPCIONAL EN LA DIFERENCIACION TEMPRANA Y TERMINAL DE LINFOCITOS B

PRE2018-083183

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MYC's Fine Line Between B Cell Development and Malignancy

  • de Barrios, Oriol|||0000-0001-5076-1455
  • Meler, Ainara|||0000-0002-0026-7325
  • Parra, Maribel|||0000-0002-9072-5763
The transcription factor MYC is transiently expressed during B lymphocyte development, and its correct modulation is essential in defined developmental transitions. Although temporary downregulation of MYC is essential at specific points, basal levels of expression are maintained, and its protein levels are not completely silenced until the B cell becomes fully differentiated into a plasma cell or a memory B cell. MYC has been described as a proto-oncogene that is closely involved in many cancers, including leukemia and lymphoma. Aberrant expression of MYC protein in these hematological malignancies results in an uncontrolled rate of proliferation and, thereby, a blockade of the differentiation process. MYC is not activated by mutations in the coding sequence, and, as reviewed here, its overexpression in leukemia and lymphoma is mainly caused by gene amplification, chromosomal translocations, and aberrant regulation of its transcription. This review provides a thorough overview of the role of MYC in the developmental steps of B cells, and of how it performs its essential function in an oncogenic context, highlighting the importance of appropriate MYC regulation circuitry.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The HDAC7-TET2 epigenetic axis is essential during early B lymphocyte development

  • Azagra, Alba|||0000-0002-9097-1251
  • Meler, Ainara|||0000-0002-0026-7325
  • de Barrios, Oriol|||0000-0001-5076-1455
  • Tomás Daza, Laureano|||0000-0002-6127-1694
  • Collazo, Olga
  • Monterde, B.
  • Obiols, Mireia|||0000-0003-3323-5239
  • Rovirosa Mulet, Llorenç|||0000-0003-2986-9001
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Cabrera Pasadas, Mònica|||0000-0001-9216-0906
  • Gusi Vives, Mar|||0000-0001-5702-153X
  • Graf, Thomas|||0000-0003-2774-4117
  • Varela, Ignacio|||0000-0002-0969-506X
  • Sardina, José Luis|||0000-0002-8493-3937
  • Javierre, B. M.|||0000-0002-8682-6748
  • Parra, Maribel|||0000-0002-9072-5763
Correct B cell identity at each stage of cellular differentiation during B lymphocyte development is critically dependent on a tightly controlled epigenomic landscape. We previously identified HDAC7 as an essential regulator of early B cell development and its absence leads to a drastic block at the pro-B to pre-B cell transition. More recently, we demonstrated that HDAC7 loss in pro-B-ALL in infants associates with a worse prognosis. Here we delineate the molecular mechanisms by which HDAC7 modulates early B cell development. We find that HDAC7 deficiency drives global chromatin de-condensation, histone marks deposition and deregulates other epigenetic regulators and mobile elements. Specifically, the absence of HDAC7 induces TET2 expression, which promotes DNA 5-hydroxymethylation and chromatin de-condensation. HDAC7 deficiency also results in the aberrant expression of microRNAs and LINE-1 transposable elements. These findings shed light on the mechanisms by which HDAC7 loss or misregulation may lead to B cell-based hematological malignancies.